Legend Biotech (LEGN) to Release Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $190.83 million for the quarter.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.39) by $0.46. The company had revenue of $186.50 million during the quarter, compared to analysts' expectations of $179.00 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm's revenue was up 134.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.40) EPS. On average, analysts expect Legend Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Legend Biotech Stock Performance

Shares of LEGN opened at $33.10 on Tuesday. The firm has a market cap of $6.08 billion, a PE ratio of -35.16 and a beta of 0.20. The company's 50 day simple moving average is $34.29 and its 200-day simple moving average is $36.62. Legend Biotech has a 12-month low of $29.27 and a 12-month high of $60.87. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27.

Analyst Ratings Changes

Several research analysts recently weighed in on LEGN shares. Morgan Stanley cut their target price on shares of Legend Biotech from $82.00 to $80.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. Royal Bank of Canada reiterated an "outperform" rating and issued a $84.00 target price on shares of Legend Biotech in a report on Tuesday, April 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of Legend Biotech in a research report on Wednesday, April 16th. Finally, Guggenheim restated a "neutral" rating on shares of Legend Biotech in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Legend Biotech presently has an average rating of "Moderate Buy" and a consensus target price of $78.82.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.